K. Šmejkal

The specificity trap in routine tumor biomarker interpretation: Advancing the 3PM-based clinical decision framework to benefits of patients

Routine tumor biomarkers remain among the most accessible tools in oncology. Yet, their clinical value is frequently weakened by a persistent specificity trap: abnormal results are often treated as cancer-specific signals, whereas normal results are sometimes used to reassure against malignancy. This critical narrative...